

Name of Sponsor: IRCCS OSPEDALE SAN RAFFAELE - Prof. Fabio Ciceri		Statement on discontinuation of the study	
Investigational Product: Cyclophosphamide Filgrastim Rituximab Etoposide		EudraCT No.: 2007-005506-42	
		Page: 1	
Report Date: 17-SEP-2021	Trial No. / Doc. No.: NHL-HIV+		
Title of Trial:	HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT		
Trial Sites:	NA		
Publications:	NA		
Clinical Phase:	II		
Statement on discontinuation of the study:	<p>Contrary to the initial hypothesis, the number of patients with HIV + lymphomas responding to the inclusion criteria has decreased over time, with a strong delay in enrollment. This has led to the decision to stop the study early. The study ended without enrolling the expected number of patients. Insufficient data for analysis.</p>		